Maverick Capital’s Supernus Pharmaceuticals SUPN Stock Holding History

Maverick Capital’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-7,409	Closed	-$223K	–	483
2023 Q2	$223K	Sell	7,409 -997	-12%	-$34.9K	﹤0.01%	385
2023 Q1	$305K	Buy	8,406 +695	+9%	+$26.7K	0.01%	413
2022 Q4	$275K	Sell	7,711 -1,175	-13%	-$40.8K	0.01%	309
2022 Q3	$301K	Buy	+8,886	New	+$289K	0.01%	225
2022 Q1	–	Sell	-4,000	Closed	-$117K	–	363
2021 Q4	$117K	Sell	4,000 -37,962	-90%	-$1.15M	﹤0.01%	175
2021 Q3	$1.12M	Sell	41,962 -15,289	-27%	-$410K	0.01%	273
2021 Q2	$1.76M	Buy	+57,251	New	+$1.76M	0.02%	183
2021 Q1	–	Sell	-1,711	Closed	-$43K	–	854
2020 Q4	$43K	Sell	1,711 -64,466	-97%	-$1.39M	﹤0.01%	627
2020 Q3	$1.38M	Buy	+66,177	New	+$1.5M	0.03%	199

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Maverick Capital's SUPN Position: Q3 2023 in Review

Maverick Capital sold out of Supernus Pharmaceuticals (SUPN) in Q3 2023, closing a stake of 7,409 shares — an estimated $223K sold.

Maverick Capital first reported a position in SUPN in Q3 2020 and held it in 9 quarters. The position peaked at $1.76M in Q2 2021. 238 funds tracked by Wall St. Rank hold SUPN as of Q3 2023.

Maverick Capital reported no remaining Supernus Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Maverick Capital sold 7,409 Supernus Pharmaceuticals shares in Q3 2023, an estimated $223K.
Maverick Capital first reported a position in Supernus Pharmaceuticals in Q3 2020 and held it in 9 quarters.
Maverick Capital's Supernus Pharmaceuticals position peaked at $1.76M in Q2 2021.
238 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2023.

Based on Maverick Capital's 13F filing for Q3 2023, filed 14 Nov 2023.